NEW YORK (GenomeWeb) – Veracyte has entered into a co-promotion agreement with Genzyme for the Afirma Gene Expression Classifier test in Brazil and Singapore, according to the firm's Form 10-K recently filed with the US Securities and Exchange Commission.

Under the terms of the agreement, Veracyte will pay Genzyme 25 percent of cash receipts from the sale of the Afirma GEC test in Brazil and Singapore over a five-year period that began on Jan. 1, 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.